Literature DB >> 19349174

Induction of apoptosis promoted by Bang52; a small molecule that downregulates Bcl-x(L).

Matteo Rossi1, Jeong-Kyu Bang, Sharlyn Mazur, Jaclyn A Iera, Darren C Phillips, Gerard P Zambetti, Daniel H Appella.   

Abstract

Cancer cells evade death by over-producing specific proteins that inhibit apoptosis. One such group of proteins is the Bcl-2 family, of which Bcl-x(L) is an important member. This protein binds and inhibits BAK, another protein that promotes apoptosis. While the development of chemical inhibitors that block Bcl-x(L)-BAK association have been the focus of intense research efforts, we demonstrate in this manuscript an alternative strategy to downregulate Bcl-x(L). We have identified a small molecule (Bang52) that induces apoptosis in a lymphoblast-derived cell line by lowering levels of Bcl-x(L). Since Bang52 bears no resemblance to any chemical binder of Bcl-x(L) we believe that degradation of the protein is stimulated by a new type of pathway. These findings highlight a novel approach to the development of small molecules that promote apoptosis.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19349174      PMCID: PMC2808702          DOI: 10.1016/j.bmcl.2009.03.067

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  46 in total

1.  PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax.

Authors:  Tao Wang; Kyunghee Lee; Abdur Rehman; Sayed S Daoud
Journal:  Biochem Biophys Res Commun       Date:  2006-11-09       Impact factor: 3.575

2.  Mitochondria primed by death signals determine cellular addiction to antiapoptotic BCL-2 family members.

Authors:  Michael Certo; Victoria Del Gaizo Moore; Mari Nishino; Guo Wei; Stanley Korsmeyer; Scott A Armstrong; Anthony Letai
Journal:  Cancer Cell       Date:  2006-05       Impact factor: 31.743

3.  Reactivation of mutant p53 and induction of apoptosis in human tumor cells by maleimide analogs.

Authors:  Vladimir J N Bykov; Natalia Issaeva; Nicole Zache; Alexandre Shilov; Monica Hultcrantz; Jan Bergman; Galina Selivanova; Klas G Wiman
Journal:  J Biol Chem       Date:  2005-07-01       Impact factor: 5.157

Review 4.  Reactivation of mutant p53: molecular mechanisms and therapeutic potential.

Authors:  G Selivanova; K G Wiman
Journal:  Oncogene       Date:  2007-04-02       Impact factor: 9.867

Review 5.  p53--a natural cancer killer: structural insights and therapeutic concepts.

Authors:  Lin Römer; Christian Klein; Alexander Dehner; Horst Kessler; Johannes Buchner
Journal:  Angew Chem Int Ed Engl       Date:  2006-10-06       Impact factor: 15.336

Review 6.  BCL-2 in the crosshairs: tipping the balance of life and death.

Authors:  L D Walensky
Journal:  Cell Death Differ       Date:  2006-06-09       Impact factor: 15.828

7.  Effects of PRIMA-1 on wild-type L1210 cells expressing mutant p53 and drug-resistant L1210 cells lacking expression of p53: necrosis vs. apoptosis.

Authors:  Ann H Cory; Jianming Chen; Joseph G Cory
Journal:  Anticancer Res       Date:  2006 Mar-Apr       Impact factor: 2.480

8.  PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion.

Authors:  H Nahi; M Merup; S Lehmann; S Bengtzen; L Möllgård; G Selivanova; K G Wiman; C Paul
Journal:  Br J Haematol       Date:  2006-01       Impact factor: 6.998

9.  Modulation of p53 transcriptional activity by PRIMA-1 and Pifithrin-alpha on staurosporine-induced apoptosis of wild-type and mutated p53 epithelial cells.

Authors:  J F Charlot; M Nicolier; J L Prétet; C Mougin
Journal:  Apoptosis       Date:  2006-05       Impact factor: 4.677

10.  A new method for the cytofluorimetric analysis of mitochondrial membrane potential using the J-aggregate forming lipophilic cation 5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolcarbocyanine iodide (JC-1).

Authors:  A Cossarizza; M Baccarani-Contri; G Kalashnikova; C Franceschi
Journal:  Biochem Biophys Res Commun       Date:  1993-11-30       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.